Volume : 13, Issue : 01, January – 2026
Title:
THE EXPANDING THERAPEUTIC LANDSCAPE OF GLP-1 RECEPTOR AGONISTS BEYOND DIABETES
Authors :
Gayatri S. Bansode. Rupal R.Walke
Abstract :
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were initially introduced as incretin-based agents for the treatment of type 2 diabetes mellitus (T2DM). Over recent years, extensive experimental, clinical, and population-based studies have revealed that these agents exert wide-ranging biological effects extending far beyond glucose regulation. GLP-1RAs influence appetite control, body weight, cardiovascular outcomes, renal function, hepatic lipid metabolism, and neuroinflammatory pathways. Advances in incretin pharmacology, including dual and multi-agonist molecules, have further broadened their therapeutic scope. This review critically examines the molecular mechanisms and clinical evidence supporting the extra-glycemic benefits of GLP-1 receptor agonists, highlighting their emerging role as multisystem disease-modifying therapies.
Keywords: GLP-1 receptor agonists; incretin signaling; cardiometabolic disease; chronic kidney disease; obesity; NAFLD; neuroprotection
Cite This Article:
Please cite this article in press Gayatri S. Bansode et al., The Expanding Therapeutic Landscape Of Glp-1 Receptor Agonists Beyond Diabetes, Indo Am. J. P. Sci, 2026; 13(01).
REFERENCES:
1. Krishnan A, et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in NAFLD and T2DM. Diabetologia. 2024.
2. Westermeier F, Fisman EZ. GLP-1 receptor agonists and cardiometabolic protection. Cardiovasc Diabetol. 2025.
3. Rowlands J, et al. Pleiotropic effects of GLP-1 on cell signaling and metabolism. Front Endocrinol. 2018.
4. Siniukovich A, et al. Impact of GLP-1 receptor agonists on cardiovascular and renal outcomes in CKD. Diabetol Metab Syndr. 2025.
5. ADA–KDIGO Consensus Report. Diabetes management in chronic kidney disease. Diabetes Care. 2022.
6. Ghosal S, et al. GLP-1 receptor agonists in NAFLD with T2DM: A meta-analysis. Sci Rep. 2021.
7. Irfan H, et al. Role of GLP-1 receptor agonists in weight loss in T2DM. Cureus. 2023.
8. Vahora I, et al. GLP-1 receptor agonists for weight loss in non-diabetic patients. Cureus. 2024.
9. Katole NT, et al. Anti-obesity effects of GLP-1 receptor agonists in adolescents. Cureus. 2024.
10. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in Context. 2015.
11. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine. 2025.
12. Son JW, Lim S. GLP-1-based therapies in obesity management. Endocrinol Metab. 2024
13. Knudsen LB, Lau J. Discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019.
14. Cai W, et al. Tirzepatide as a novel strategy for obesity. Front Public Health. 2024.
15. Cooper ME, van Raalte DH. GLP-1 agonists in chronic kidney disease. J Clin Invest. 2025.
16. Mahapatra MK, et al. Therapeutic potential of semaglutide beyond diabetes. Pharm Res. 2022.
17. Koye DN, et al. Global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018.
18. Hoang V, et al. Liraglutide improves hypertension in PCOS model. PLoS ONE. 2015.
19. Bruns VI N, et al. GLP-1 and substance use disorders. Pharmacol Res. 2024. GB NAFDAL
20. Xu D, et al. Potential roles of GLP-1 receptor agonists in nondiabetic populations. Cardiovasc Ther. 2022.
21. Nauck MA, et al. Preserved incretin activity of GLP-1 in type 2 diabetes. J Clin Invest. 1993.
22. Nauck MA, et al. GLP-1 vs GIP insulinotropic effects in T2DM. J Clin Invest. 1993.
23. Tan Q, et al. Recent advances in incretin-based pharmacotherapies. Front Endocrinol. 2022.
24. Flint A, et al. GLP-1 promotes satiety and suppresses energy intake. J Clin Invest. 1998.
25. Tan Q, et al. GLP-1 signaling and obesity pharmacotherapy. Front Endocrinol. 2022.
26. Duan K, et al. Effect of GLP-1 receptor agonists on fat distribution. J Diabetes Investig. 2022.
27. Christensen M, et al. GIP as a bifunctional regulator of insulin and glucagon. Diabetes. 2011.
28. Tan Q, et al. Dual incretin agonism and metabolic control. Front Endocrinol. 2022.
29. Cooper ME, van Raalte DH. GLP-1 agonists in chronic kidney disease. J Clin Invest. 2025.
30. Kopp KO, et al. GLP-1 receptor agonists and neuroinflammation. Pharmacol Res. 2022.
31. Kalinderi K, et al. GLP-1 receptor agonists in Parkinson’s disease. Int J Mol Sci. 2024.
32. Monti G, et al. GLP-1 receptor agonists in neurodegeneration. Cells. 2022.
33. Zhang L, et al. Neuroprotective effects of semaglutide in Parkinson’s disease models. Neuropeptides.
34. Monti G, et al. GLP-1 and neurovascular unit integrity. Cells. 2022.
35. Glotfelty EJ, et al. GLP-1-based receptor agonists as a treatment for Parkinson’s disease. Expert Opin Investig Drugs. 2020.
36. Kupnicka P, et al. GLP-1 receptor agonists: a promising therapy for modern lifestyle diseases. Pharmaceuticals. 2024.
37. Doyle ME, Egan JM. Mechanisms of action of GLP-1 in the pancreas. Pharmacol Ther. 2007.
38. Zheng Z, et al. GLP-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024.
39. Duan K, et al. Effect of GLP-1 receptor agonists on fat distribution. J Diabetes Investig. 2022.
40. Lin Y, et al. Cardiovascular and renal effects of GLP-1 receptor agonists in advanced diabetic kidney disease. Cardiovasc Diabetol. 2023.
41. Chen X, et al. Effects of GLP-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes. Diabetol Metab Syndr. 2024.
42. Lin Y, et al. GLP-1RA versus DPP-4 inhibitors in diabetic kidney disease. Cardiovasc Diabetol. 2023.
43. Lin Y, et al. Renal outcomes of GLP-1 receptor agonists in advanced CKD. Cardiovasc Diabetol. 2023.
44. Zile MR, et al. Effects of tirzepatide in heart failure with preserved ejection fraction and obesity. Circulation. 2025.
45. Monti G, et al. GLP-1 receptor agonists in neurodegeneration. Cells. 2022.